| 000 | 01709 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517014558.0 | ||
| 264 | 0 | _c20160101 | |
| 008 | 201601s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/dom.12444 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDaniels, G H | |
| 245 | 0 | 0 |
_aLEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _cMay 2015 |
||
| 300 |
_a477-86 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 |
_aCalcitonin _xblood |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGlomerular Filtration Rate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 |
_aLiraglutide _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSex Factors |
| 700 | 1 | _aHegedüs, L | |
| 700 | 1 | _aMarso, S P | |
| 700 | 1 | _aNauck, M A | |
| 700 | 1 | _aZinman, B | |
| 700 | 1 | _aBergenstal, R M | |
| 700 | 1 | _aMann, J F E | |
| 700 | 1 | _aDerving Karsbøl, J | |
| 700 | 1 | _aMoses, A C | |
| 700 | 1 | _aBuse, J B | |
| 700 | 1 | _aTuttle, R M | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 17 _gno. 5 _gp. 477-86 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/dom.12444 _zAvailable from publisher's website |
| 999 |
_c24598704 _d24598704 |
||